Market closedADR
Immunocore/$IMCR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Immunocore
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
Ticker
$IMCR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
497
Website
Immunocore Metrics
BasicAdvanced
$1.4B
Market cap
-
P/E ratio
-$0.95
EPS
0.72
Beta
-
Dividend rate
Price and volume
Market cap
$1.4B
Beta
0.72
52-week high
$76.98
52-week low
$28.27
Average daily volume
247K
Financial strength
Current ratio
3.778
Quick ratio
3.624
Long term debt to equity
114.274
Total debt to equity
127.324
Interest coverage (TTM)
-5.26%
Management effectiveness
Return on assets (TTM)
-5.22%
Return on equity (TTM)
-12.83%
Valuation
Price to revenue (TTM)
4.865
Price to book
3.83
Price to tangible book (TTM)
3.83
Price to free cash flow (TTM)
72.538
Growth
Revenue change (TTM)
25.09%
Earnings per share change (TTM)
-32.96%
3-year revenue growth (CAGR)
100.70%
3-year earnings per share growth (CAGR)
-37.93%
What the Analysts think about Immunocore
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Immunocore Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Immunocore Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Immunocore News
AllArticlesVideos
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
GlobeNewsWire·2 weeks ago
3 Fast-Growing Stocks Analysts See Doubling in Price
MarketBeat·1 month ago
Immunocore to present at upcoming investor conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Immunocore stock?
Immunocore (IMCR) has a market cap of $1.4B as of December 15, 2024.
What is the P/E ratio for Immunocore stock?
The price to earnings (P/E) ratio for Immunocore (IMCR) stock is 0 as of December 15, 2024.
Does Immunocore stock pay dividends?
No, Immunocore (IMCR) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next Immunocore dividend payment date?
Immunocore (IMCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunocore?
Immunocore (IMCR) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.